header bar
  LeukemiaLinks - Your Link to the Latest Leukemia News  


JANUARY 2008 800.955.4572 Email the IRC Forward to a Friend
 

Welcome to LeukemiaLinks, your monthly source of leukemia news, research updates, clinical trials and events sponsored by The Leukemia & Lymphoma Society (LLS). For even more information, regularly visit our Patient Services and Disease Information Web sections.

news image

Latest Leukemia News

Study Unlocks Mystery of Child Leukemia Relapse
A certain gene abnormality raises the chance of relapse for children with the most common form of childhood cancer, a discovery that could change the way doctors treat them, U.S. researchers report.  :: READ MORE NEWS::

LLS Features    ::READ MORE::
.....................................................................................................................................

Research Roundup
   ::READ MORE::
.....................................................................................................................................
IRC Question of the Month   
:: READ MORE::


Inspirational Stories

Inspirational ImageLearn how individuals touched by blood cancer cope. The LLS LifeMosaic Web feature offers hundreds of inspiring stories by patients and families. Read them or submit your own. This month, read about Julie's battle with AML.

Here to Help

For even more information, regularly visit the LLS Web site,
www.LLS.org, where many of our education programs are archived free of charge for convenient access 24/7.

If you haven't found what you're looking for in LeukemiaLinks , please call our Information Resource Center (IRC) to speak with trained information specialists. IRC staff are available Monday through Friday, 9 a.m. to 6 p.m. ET, toll free at (800) 955-4572; email
infocenter@lls.org; or click the "Live Patient Help" button on the www.LLS.org homepage.

 

 

Researcher Image

Commentary
LLS's Deborah Banker, Ph.D., discusses some of the latest innovations presented at the recent American Society of Hematology annual meeting.

 


Clinical Trials

We invite you to use our LLS-supported TrialCheck® Web site, a clinical trial search service that offers patients and caregivers immediate access to listings of all leukemia clinical trials. Answer just a few simple questions and a list of available clinical trials related to your cancer will appear in an easy to read list of search results. 

You may also want to visit the National Cancer Institute's Cancer Trials Support Unit, providing resources and information on Phase III cancer treatment trials supported by the National Cancer Institute. :: SELECTED TRIALS::



Newsfeeds & Podcasts

Now you can get RSS Feeds and Podcasts from LLS.
:: CLICK HERE TO SIGN UP::

RSS - XML - Podcast - iTunes

Free eNewsletters
Free LLS eNewsletters deliver the latest information on research and treatment options, patient services programs and fundraising events.
::CLICK HERE TO SIGN UP ::


bottom bar

Latest Leukemia News

news image

Fludarabine/Cyclophosphamide/Rituximab Successful against CLL
Sequential therapy using fludarabine, high-dose cyclophosphamide and rituximab produces high-quality responses in previously untreated patients with chronic lymphocytic leukemia, according to researchers at Memorial Sloan-Kettering Cancer Center in New York.

Palonosetron Useful for Preventing Vomiting During Chemotherapy
Combined with dexamethasone, palonosetron is comparable to granisetron in preventing chemotherapy-induced nausea and vomiting in the acute phase and is superior to granisetron in the delayed phase, new research shows. 

The Maker of Miracles
For Brian Druker, M.D., pioneer of the drug Gleevec®, innovation requires putting up with grueling work hours and taking some big risks. Read more.

Novel Pathway Involved in Therapy-Resistant Cancers Discovered
Scientists at The Babraham Institute have begun to unpick the complex mechanisms underpinning the development of drug resistant cancers.

> Back to the top

LLS Features

calendar image

Archived Educational Events
Experience archived teleconferences and Webcasts free of charge, anytime.

My Personal CML Journey
LLS is proud to offer My Personal CML Journey, an interactive, online video education program. The feature follows the stories and experiences of two chronic myelogenous leukemia (CML) survivors. Learn more.

Free LLS Fact Sheet: Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia
Read online or order a free copy. 

The Leukemia & Lymphoma Society is committed to curing blood cancers and helping patients and their families. Learn the many ways you can help advance LLS's mission.  


> Back to the top

Research Roundup

links_image_micro2

Curative strategies in acute promyelocytic leukemia  ::READ MORE:: 

Neuropsychological outcome in very young hematopoietic SCT recipients in relation to pretransplant conditioning  ::READ MORE::


Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly  ::READ MORE:: 

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia treated with alemtuzumab and rituximab  ::READ MORE::

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia  ::READ MORE:: 

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells  ::READ MORE::


>
Back to the top

Clinical Trials
Clinical Trials Image

Selected Trials

A Phase Ib Study of ISF35 in Combination with Chemotherapy (FCR) in Subjects with Relapsed, Refractory and/or 17p- CLL  ::READ MORE:: 

A Phase III Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients with B-Cell CLL Following Second Line Therapy  ::READ MORE:: 

A Phase III Study of Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase CML  ::READ MORE:: 

Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant  ::READ MORE:: 

Phase II: Panobinostat in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia  ::READ MORE::

Phase III: Compare Bosutinib to Imatinib in Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML  ::READ MORE:: 

> Back to the top

IRC Question of the Month
Q&A

Q: At what age is a patient not eligible for a clinical trial?

A: All clinical trials have eligibility guidelines. These guidelines may be based on the patient's age, the type and stage of disease, previous treatment history and any co-existing medical conditions; for example, diabetes or high blood pressure.

Guidelines are sometimes called "inclusion criteria" (the characteristics of patients who may take part in the trial) and "exclusion criteria" (the characteristics of patients who cannot take part in the trial). Inclusion and exclusion criteria are used to ensure that patient participation is appropriate for the goals of the trial and to produce reliable medical research results. 

Some older patients may assume clinical trials are not for them. This is not necessarily true. Studies have shown that age alone does not reflect a person's overall health and ability to benefit from a clinical trial. Many older adults have been treated successfully in clinical trials.  According to reports, overall, patients in clinical trials receive more follow-up care and better disease and side-effect management, compared with patients receiving treatment outside of clinical trial settings. 

Nationwide participation in clinical trials by older adults is growing.  Participation across age-groups helps doctors determine if a treatment is safe and effective for people of different ages. Some trials are not appropriate for older adults or a subgroup of older adults, such as those with serious medical complications. But more trials are being offered to older adults, and there are also trials designed specifically for them. 

It is important to discuss clinical trials as an option with your doctor.  Please also contact LLS's Information Resource Center (IRC) at ( 800) 955-4572 to find out more about clinical trials and other treatment options for older adults with leukemia. You may also order the free LLS booklet Understanding Clinical Trials for Blood Cancers .

As always, we encourage patients, their families and caregivers to turn to the IRC for information and support. IRC specialists are available 9 a.m. to 6 p.m. ET. Call us with your questions at (800) 955-4572.

> Back to the top

Supported by an unrestricted
educational grant from
Cephalon Oncology
Donate Now
Contact Us: The Leukemia & Lymphoma Society, 1311 Mamaroneck Ave., White Plains, NY 10605, (800) 955-4572
Visit our e-Store & Special Offers page where you can support businesses that support LLS.